Keywords: immupharma, lupus, drug, enters, ph, ii, london
ImmuPharma's lupus drug enters Ph II
Article | 17 July 2006
London, UK-headquartered drug discovery company ImmuPharma says that its developmental lupus treatment, IPP-201101, has entered Phase II assessment. This follows ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
